Roche advances AI-driven cancer diagnostics by expanding its digital pathology open environment
Roche (SIX: RO, ROG; OTCQX: RHHBY) has expanded its digital pathology open environment by integrating over 20 advanced AI algorithms from eight new collaborators. This expansion aims to enhance cancer research and diagnosis through Roche's navify® Digital Pathology enterprise software. The AI tools are designed to provide valuable insights in pathology, supporting precision medicine and targeted treatments for cancer patients.
The new collaborators include Deep Bio, DiaDeep, Lunit, Mindpeak, Owkin, Qritive, Sonrai Analytics, and Stratipath. Their algorithms cover various aspects of cancer detection and analysis, including prostate cancer grading, breast cancer biomarker quantification, and microsatellite stability screening in colorectal cancer. This integration demonstrates Roche's commitment to advancing personalized healthcare and improving patient outcomes in cancer diagnostics and treatment.
Roche (SIX: RO, ROG; OTCQX: RHHBY) ha ampliato il suo ambiente di patologia digitale aperto integrando oltre 20 algoritmi avanzati di intelligenza artificiale da otto nuovi collaboratori. Questa espansione mira a migliorare la ricerca e la diagnosi del cancro attraverso il software aziendale navify® Digital Pathology di Roche. Gli strumenti di IA sono progettati per fornire approfondimenti preziosi in patologia, supportando la medicina di precisione e i trattamenti mirati per i pazienti oncologici.
I nuovi collaboratori includono Deep Bio, DiaDeep, Lunit, Mindpeak, Owkin, Qritive, Sonrai Analytics e Stratipath. I loro algoritmi coprono vari aspetti della rilevazione e analisi del cancro, inclusi la classificazione del cancro alla prostata, la quantificazione dei biomarker del cancro al seno e lo screening della stabilità dei microsatelliti nel cancro colorettale. Questa integrazione dimostra l'impegno di Roche nel promuovere la salute personalizzata e nel migliorare i risultati per i pazienti nella diagnosi e nel trattamento del cancro.
Roche (SIX: RO, ROG; OTCQX: RHHBY) ha ampliado su entorno de patología digital abierta integrando más de 20 algoritmos avanzados de inteligencia artificial de ocho nuevos colaboradores. Esta expansión tiene como objetivo mejorar la investigación y el diagnóstico del cáncer a través de el software empresarial navify® Digital Pathology de Roche. Las herramientas de IA están diseñadas para proporcionar información valiosa en patología, apoyando la medicina de precisión y los tratamientos dirigidos para los pacientes con cáncer.
Los nuevos colaboradores incluyen a Deep Bio, DiaDeep, Lunit, Mindpeak, Owkin, Qritive, Sonrai Analytics y Stratipath. Sus algoritmos abarcan varios aspectos de la detección y análisis del cáncer, incluyendo la clasificación del cáncer de próstata, la cuantificación de biomarcadores del cáncer de mama y el cribado de estabilidad de microsatélites en el cáncer colorrectal. Esta integración demuestra el compromiso de Roche con el avance de la atención sanitaria personalizada y la mejora de los resultados para los pacientes en el diagnóstico y tratamiento del cáncer.
로슈(Roche) (SIX: RO, ROG; OTCQX: RHHBY)는 8개의 새로운 협력사로부터 20개 이상의 고급 인공지능 알고리즘을 통합하여 디지털 병리학 개방 환경을 확장했습니다. 이번 확장은 로슈의 navify® Digital Pathology 기업 소프트웨어를 통해 암 연구 및 진단을 향상시키기 위한 것입니다. AI 도구는 병리학에서 귀중한 통찰력을 제공하도록 설계되어 있으며, 정밀 의학과 암환자를 위한 표적 치료를 지원합니다.
새로운 협력사에는 Deep Bio, DiaDeep, Lunit, Mindpeak, Owkin, Qritive, Sonrai Analytics, Stratipath가 포함됩니다. 이들의 알고리즘은 전립선암 등급, 유방암 바이오마커 정량화, 대장암에서의 마이크로새틀라이트 안정성 선별 등 암 탐지 및 분석의 다양한 측면을 다룹니다. 이 통합은 로슈가 개인 맞춤형 건강 관리를 발전시키고 암 진단 및 치료에서 환자 결과를 개선하기 위한 의지를 보여줍니다.
Roche (SIX: RO, ROG; OTCQX: RHHBY) a élargi son environnement de pathologie numérique ouverte en intégrant plus de 20 algorithmes avancés d'intelligence artificielle provenant de huit nouveaux collaborateurs. Cette expansion vise à améliorer la recherche et le diagnostic du cancer grâce à au logiciel d'entreprise navify® Digital Pathology de Roche. Les outils d'IA sont conçus pour fournir des informations précieuses en pathologie, soutenant la médecine de précision et les traitements ciblés pour les patients atteints de cancer.
Les nouveaux collaborateurs incluent Deep Bio, DiaDeep, Lunit, Mindpeak, Owkin, Qritive, Sonrai Analytics et Stratipath. Leurs algorithmes couvrent divers aspects de la détection et de l'analyse du cancer, y compris la classification du cancer de la prostate, la quantification des biomarqueurs du cancer du sein et le dépistage de la stabilité des microsatellites dans le cancer colorectal. Cette intégration démontre l'engagement de Roche à faire progresser les soins de santé personnalisés et à améliorer les résultats pour les patients dans le diagnostic et le traitement du cancer.
Roche (SIX: RO, ROG; OTCQX: RHHBY) hat seine offene digitale Pathologieumgebung erweitert, indem über 20 fortgeschrittene KI-Algorithmen von acht neuen Partnern integriert wurden. Diese Erweiterung zielt darauf ab, die Krebsforschung und -diagnose durch die Unternehmenssoftware navify® Digital Pathology von Roche zu verbessern. Die KI-Tools sind darauf ausgelegt, wertvolle Einblicke in die Pathologie zu liefern und die Präzisionsmedizin sowie zielgerichtete Behandlungen für Krebspatienten zu unterstützen.
Zu den neuen Partnern gehören Deep Bio, DiaDeep, Lunit, Mindpeak, Owkin, Qritive, Sonrai Analytics und Stratipath. Ihre Algorithmen decken verschiedene Aspekte der Krebsdetektion und -analyse ab, einschließlich der Einstufung von Prostatakrebs, der Quantifizierung von Biomarkern bei Brustkrebs und dem Screening der Mikrosatellitenstabilität bei kolorektalem Krebs. Diese Integration zeigt Roches Engagement, die personalisierte Gesundheitsversorgung voranzutreiben und die Patientenergebnisse in der Krebsdiagnose und -behandlung zu verbessern.
- Integration of over 20 advanced AI algorithms from eight new collaborators
- Expansion of digital pathology open environment to enhance cancer research and diagnosis
- Potential improvement in precision medicine and targeted treatments for cancer patients
- Diverse range of AI tools covering various aspects of cancer detection and analysis
- None.
- The Roche Digital Pathology Open Environment brings together a wide array of innovative AI-based pathology tools to help clinicians improve patient care and expand personalised healthcare.
- Roche is now integrating more than 20 artificial intelligence (AI) algorithms from
eight new collaborators into its digital pathology open environment. - AI technology helps enhance pathology with high value insights, which can benefit cancer patients through precision medicine leading to targeted treatment.
The seamless integration is facilitated through Roche's navify® Digital Pathology enterprise software, an application for the pathologist's workflow, which now incorporates a diverse range of AI-driven algorithms, creating easy access to third-party innovation. These AI tools are designed to enhance pathology insights, helping benefit cancer patients through precision medicine and enabling targeted treatments.
"We are excited to welcome these new collaborators into our digital pathology ecosystem," said Jill German, Head of Pathology Lab for Roche Diagnostics. "By combining our leadership in tissue diagnostics with a broad offering of state-of-the-art AI technology, we aim to revolutionise cancer research, diagnostics and treatment, ultimately helping clinicians improve the lives of patients worldwide."
The collaborators are:
- Deep Bio: Algorithm for prostate cancer detection, grading, and tumour quantification
- DiaDeep: Algorithms for breast cancer biomarker quantification
- Lunit: Tumour proportion score (TPS) analysis for non-small cell lung cancer
- Mindpeak: Algorithms for breast biomarkers and pan tumour PD-L1 for lung, gastric, esophageal, bladder and breast cancers
- Owkin: Algorithm for the screening of microsatellite stability in colorectal cancer
- Qritive: Algorithms for screening and grading of prostate cancer, analysing lymph nodes for metastasis, and screening for colon cancer
- Sonrai Analytics: Algorithm for determining microsatellite instability (MSI) status in colorectal cancer
- Stratipath: Algorithm for risk profiling of invasive breast cancer
With these new collaborations and integrations, Roche emphasises its commitment to improving patient outcomes and advancing personalised healthcare by providing scientists and clinicians with the resources they need to deliver precise and effective cancer diagnoses.
About Roche Digital Pathology
As the leading provider of pathology lab solutions, Roche delivers an end-to-end digital pathology solution from tissue staining to producing high-quality digital images that can be reliably assessed using automated AI-based clinical image analysis algorithms. Roche minimises variables that can impact analysis, and it is this end-to-end development that produces the quality results healthcare providers and researchers can depend on. With the acceleration of immunotherapy and the development of more complex assays, Roche is moving these traditionally research-oriented AI tools into routine clinical practice and is committed to investing in and shaping the future of pathology. The Roche Digital Pathology Open Environment* serves as a collaborative platform that brings together innovative AI-based pathology tools.
About Roche
Founded in 1896 in
In recognising our endeavour to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the fifteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.
Genentech, in
For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
* Some algorithms are Research Use Only and not for use in diagnostic procedures. Please consult with local markets on the regulatory status of these algorithms.
Roche Media Relations
Jo Lynn Garing, +1 317-363-7286 or jo_lynn.garing@roche.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/roche-advances-ai-driven-cancer-diagnostics-by-expanding-its-digital-pathology-open-environment-302241196.html
SOURCE Roche
FAQ
What is the purpose of Roche's expansion of its digital pathology open environment?
How many new AI algorithms has Roche (RHHBY) integrated into its digital pathology platform?
What types of cancer diagnostics are covered by the new AI algorithms in Roche's (RHHBY) digital pathology platform?
Who are the new collaborators in Roche's expanded digital pathology open environment?
